252 related articles for article (PubMed ID: 27659023)
1. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus.
Sakuma T; Masaki K; Abe-Chayama H; Mochida K; Yamamoto T; Chayama K
Genes Cells; 2016 Nov; 21(11):1253-1262. PubMed ID: 27659023
[TBL] [Abstract][Full Text] [Related]
2. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
[TBL] [Abstract][Full Text] [Related]
3. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9.
Li H; Sheng C; Wang S; Yang L; Liang Y; Huang Y; Liu H; Li P; Yang C; Yang X; Jia L; Xie J; Wang L; Hao R; Du X; Xu D; Zhou J; Li M; Sun Y; Tong Y; Li Q; Qiu S; Song H
Front Cell Infect Microbiol; 2017; 7():91. PubMed ID: 28382278
[TBL] [Abstract][Full Text] [Related]
4. Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA.
Kayesh MEH; Amako Y; Hashem MA; Murakami S; Ogawa S; Yamamoto N; Hifumi T; Miyoshi N; Sugiyama M; Tanaka Y; Mizokami M; Kohara M; Tsukiyama-Kohara K
Virus Res; 2020 Dec; 290():198191. PubMed ID: 33049308
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 Targeting of Hepatitis B Virus Covalently Closed Circular DNA Generates Transcriptionally Active Episomal Variants.
Martinez MG; Combe E; Inchauspe A; Mangeot PE; Delberghe E; Chapus F; Neveu G; Alam A; Carter K; Testoni B; Zoulim F
mBio; 2022 Apr; 13(2):e0288821. PubMed ID: 35389262
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X.
Karimova M; Beschorner N; Dammermann W; Chemnitz J; Indenbirken D; Bockmann JH; Grundhoff A; Lüth S; Buchholz F; Schulze zur Wiesch J; Hauber J
Sci Rep; 2015 Sep; 5():13734. PubMed ID: 26334116
[TBL] [Abstract][Full Text] [Related]
7. The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA.
Yang HC; Chen PJ
Virus Res; 2018 Jan; 244():304-310. PubMed ID: 28627393
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA.
Ohno M; Otsuka M; Kishikawa T; Yoshikawa T; Takata A; Koike K
World J Gastroenterol; 2015 Jun; 21(23):7084-8. PubMed ID: 26109795
[TBL] [Abstract][Full Text] [Related]
9. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus.
Kostyushev D; Brezgin S; Kostyusheva A; Zarifyan D; Goptar I; Chulanov V
Cell Mol Life Sci; 2019 May; 76(9):1779-1794. PubMed ID: 30673820
[TBL] [Abstract][Full Text] [Related]
10. Application of CRISPR/Cas9 Technology to HBV.
Lin G; Zhang K; Li J
Int J Mol Sci; 2015 Nov; 16(11):26077-86. PubMed ID: 26540039
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse.
Zhu W; Xie K; Xu Y; Wang L; Chen K; Zhang L; Fang J
Virus Res; 2016 Jun; 217():125-32. PubMed ID: 27049051
[TBL] [Abstract][Full Text] [Related]
12. [Small Molecular Inhibitors of DNA Double Strand Break Repair Pathways Increase the ANTI-HBV Activity of CRISPR/Cas9].
Kostyusheva AP; Kostyushev DS; Brezgin SA; Zarifyan DN; Volchkova EV; Chulanov VP
Mol Biol (Mosk); 2019; 53(2):311-323. PubMed ID: 31099781
[TBL] [Abstract][Full Text] [Related]
13. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
[TBL] [Abstract][Full Text] [Related]
14. Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9.
Kurihara T; Fukuhara T; Ono C; Yamamoto S; Uemura K; Okamoto T; Sugiyama M; Motooka D; Nakamura S; Ikawa M; Mizokami M; Maehara Y; Matsuura Y
Sci Rep; 2017 Jul; 7(1):6122. PubMed ID: 28733609
[TBL] [Abstract][Full Text] [Related]
15. An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation.
Li H; Sheng C; Liu H; Liu G; Du X; Du J; Zhan L; Li P; Yang C; Qi L; Wang J; Yang X; Jia L; Xie J; Wang L; Hao R; Xu D; Tong Y; Zhou Y; Zhou J; Sun Y; Li Q; Qiu S; Song H
Int J Biol Sci; 2016; 12(9):1104-13. PubMed ID: 27570484
[TBL] [Abstract][Full Text] [Related]
16. Recent Progress and Future Prospective in HBV Cure by CRISPR/Cas.
Yang YC; Yang HC
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062208
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV.
Peng C; Lu M; Yang D
Virol Sin; 2015 Oct; 30(5):317-25. PubMed ID: 26511989
[TBL] [Abstract][Full Text] [Related]
18. Targeting hepatitis B virus cccDNA using CRISPR/Cas9.
Kennedy EM; Kornepati AV; Cullen BR
Antiviral Res; 2015 Nov; 123():188-92. PubMed ID: 26476375
[TBL] [Abstract][Full Text] [Related]
19. One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors.
Schiwon M; Ehrke-Schulz E; Oswald A; Bergmann T; Michler T; Protzer U; Ehrhardt A
Mol Ther Nucleic Acids; 2018 Sep; 12():242-253. PubMed ID: 30195763
[TBL] [Abstract][Full Text] [Related]
20. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9.
Kostyushev D; Kostyusheva A; Brezgin S; Zarifyan D; Utkina A; Goptar I; Chulanov V
Sci Rep; 2019 Feb; 9(1):1847. PubMed ID: 30755668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
